A rapid-learning health system

Health Affairs

Volumn 26, Issue 2, 2007, Pages

  Etheredge, Lynn M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; INFORMATION SYSTEM; LEARNING; MALE; MEDICAID; MEDICAL INFORMATICS; MEDICAL RECORD; MEDICARE; NATIONAL HEALTH INSURANCE; ORGANIZATION AND MANAGEMENT; STANDARD; SYSTEM ANALYSIS; TOTAL QUALITY MANAGEMENT; UNITED STATES; UTILIZATION REVIEW;

DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFORMATION SYSTEMS; LEARNING; MALE; MEDICAID; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MEDICARE; NATIONAL HEALTH INSURANCE, UNITED STATES; PRIVATE SECTOR; PUBLIC HEALTH INFORMATICS; PUBLIC SECTOR; REGIONAL MEDICAL PROGRAMS; SYSTEMS INTEGRATION; TOTAL QUALITY MANAGEMENT; UNITED STATES;

EID: 33947311347     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.2.w107     Document Type: Article

References (29)

1. E.H. Wagner et al., "Building a Research Consortium of Large Health Systems: The Cancer Research Network," Journal of the National Cancer Institute: Monographs no. 35 (2005): 3-11.
2. Centers for Disease Control and Prevention, "Vaccine Safety Datalink Project (VSD)," 23 October 2006, http://www.cdc.gov/od/science/iso/ research_activties/vsdp.htm (accessed 7 November 2006).
3. American Medical Group Association, "Anceta/AMGA Collaborative Data Warehouse: Background," December 2006, http://www.amga.org/QMR/Anceta/ bg_anceta.asp (accessed 12 December 2006).
4. J. Avorn, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (New York: Knopf, 2004), 380.
5. J. Abramson, Overdosed America: The Broken Promise of American Medicine (New York: HarperCollins, 2004), 95.
6. For history, see D.M. Eddy, "Evidence-Based Medicine: A Unified Approach," Health Affairs 24, no. 1 (2005): 9-17.
7. For prescription drugs, see J.P. Kassirer, On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health (New York: Oxford University Press, 2004);
8. Avorn, Powerful Medicines;
9. and Abramson, Overdosed America.
10. Abramson, Overdosed America, 95.
11. J.P. Ioannidis, "Contradicted and Initially Stronger Effects in Highly Cited Clinical Research," Journal of the American Medical Association 294, no. 2 (2005): 218-228.
12. On technology, see R.A. Deyo and D.L. Patrick, Hope or Hype: The Obsession with Medical Advances and the High Cost of False Promises (New York: AMACOM, 2005).
13. W.E. Evans and H.L. McLeod, "Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects," New England Journal of Medicine 348, no. 6 (2003): 538-549.
14. A.B. Cohen et al., Technology in American Health Policy (Ann Arbor: University of Michigan Press, 2004);
15. and P.J. Neumann, Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers (New York: Oxford University Press, 2005).
16. A listing of these papers is available at http://content.healthaffairs. org/cgi/content/full/hlthaff.26.2.w107/DC2.
17. For example, see C. Smith et al., "National Health Spending in 2004: Recent Slowdown Led by Prescription Drug Spending," Health Affairs 25, no. 1 (2006): 186-196.
18. Avorn, Powerful Medicines, 381.
19. See U.S. Department of Health and Human Services, "Office for Civil Rights - HIPAA," 2 November 2006, http://www.hhs.gov/ocr/hipaa (accessed 7 November 2006).
20. L. Rybowski, "Protecting the Confidentiality of Health Information,"National Health Policy Forum background paper (Washington: George Washington University, July 1998).
21. See the Epic Systems home page, http://www.epicsystems.com/index.php.
22. E.A. McGlynn et al., The First National Report Card on Quality of Care in America (Santa Monica: RAND, 2006).
23. Refining each DRG to pay for scientifically validated "best practices" would be one path toward a full evidence-based protocol system.
24. CureSearch, "Frequently Asked Questions," http://www. curesearch.org/our_research/index_sub.aspx?id=1488 (accessed 2 July 2006).
25. Kaiser Commission on Medicaid and the Uninsured, "Dual Eligibles: Medicaid's Role in Filling Medicare's Gaps," March 2004, http://www.kff.org/medicaid/7058.cfm (accessed 14 December 2006).
26. National Cancer Institute, Restructuring the National Cancer Clinical Trials Enterprise, June 2005, http://integratedtrials.nci.nih.gov/ict/ CTWG_report_June2005.pdf (accessed 12 December 2006);
27. and National Institutes of Health, Office of Portfolio Analysis and Strategic Initiatives, "NIH Roadmap," 25 October 2006, http://nihroadmap.nih.gov/index.asp (accessed 7 November 2006).
28. S.R. Tunis, D.B. Stryer, and C.M. Clancy, "Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy," Journal of the American Medical Association 290, no. 12 (2003): 1624-1632.
29. Avorn, Powerful Medicines, 383-384.